key: cord-0871484-egir3y76
authors: Gao, Shenghua; Huang, Tianguang; Song, Letian; Xu, Shujing; Cheng, Yusen; Cherukupalli, Srinivasulu; Kang, Dongwei; Zhao, Tong; Sun, Lin; Zhang, Jian; Zhan, Peng; Liu, Xinyong
title: Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors
date: 2021-08-31
journal: Acta Pharm Sin B
DOI: 10.1016/j.apsb.2021.08.027
sha: e9ebade71ccdcee1647b40c2d7471a60e10cfd6c
doc_id: 871484
cord_uid: egir3y76

Novel therapies are urgently needed to improve global treatment of SARS-CoV-2 infection. Herein, we briefly provide a concise report on the medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors with representative examples in different strategies from the medicinal chemistry perspective.

the emergence of new coronavirus mutants in the future 21 . To be noted, these three approaches are often used in combination to facilitate drug development. Besides, natural products derived from herbal plants has also been an important source of lead molecules for SARS-CoV-2 teratment.

In this review, we briefly provided a concise report on the medicinal chemistry strategies to develop effective SARS-CoV-2 inhibitors with representative examples from the medicinal chemistry perspective.

The discovery of lead compounds is a crucial step in the research and development of new drugs. Based on the experience of the discovery and development of SARS-CoV and MERS-CoV inhibitors, some general medicinal chemistry strategies can facilitate the discovery of SARS-CoV-2 candidate drugs in this emergent situation. Drug repurposing, large-scale screening in silico or in vitro, target-based rational drug design and exploitation of natural products and traditional Chinese medicine are several representative strategies. Herein, we focus on medicinal chemistry strategies and their successful application cases towards the discovery of safe and efficient SARS-CoV-2 inhibitors.

Repurposing or repositioning the existing drugs is a approach for generating novel clinical usages that beyond the scope of its original medical instruction for known approved or investigational drugs 22 . New drug development is generally acknowledged as time-consuming and expensive. However, drug repositioning is a shortcut to the discovery of effective coronaviral inhibitors in this pandemic situation.

Here we reviewed the strategy of repurposing of existing broad-spectrum antiviral drugs and repositioning of privileged structure based on target similarity. And several representative examples for the discovery of SARS-CoV-2 candidate drugs are also discussed.

One feasible method for the discovery of effective anti-SARS-CoV-2 drugs with clinical potential would be the reusing of existing broad-spectrum antiviral drugs 23 .

There are generally some classical methods that can be used to develop or screen for novel broad-spectrum coronaviral inhibitors. The first method is the repurposing of nucleoside analogues as the inhibitors of SARS-CoV-2 RdRp which is conserved J o u r n a l P r e -p r o o f across different coronavirus family and plays an important part in coronavirus life cycle 24 . It makes RdRp an ideal target for broad-spectrum coronaviral drugs.

Nucleoside analogues are converted into its active triphosphate metabolite by intracellular kinase and incorporated into the growing RNA chain leading to the termination of the replicative cycle, which accounts for their antivirus activity 25 .

However, CoVs are resistant to some nucleoside analogues such as ribavirin (1, Fig. 2) because of the proofreading activity of 3ʹ-5ʹ exoribonuclease (ExoN) 26 .

Remdesivir (2, Fig. 2) is the representative example of RdRp inhibitors with broad-spectrum coronaviral inhibitory activity. Remdesivir showed inhibitory activity of blocking the replication of SARS-CoV, MERS-CoV and SARS-CoV-2 in HAE cells (EC50s = 69, 74 and 0.77 μmol/L, respectively) 27, 28 . It was demonstrated that the proofreading activity could be covered by an increased and nontoxic concentration of remdesivir 29 .

A number of clinical trials concerning remdesivir's therapeutic effect of COVID-19 patients with respiratory tract infection have been conducted worldwide. In May 2020, the Gilead Sciences published their final report, claiming remdesivir leads to the better clinical outcome in hospitalized COVID-19 patients, including shortened recovery time and depressed respiratory system infection (NCT04280705) 30 COVID-19 were conducted, and the completed trials were reported to be effective for   COVID-19. It can alleviate the clinical symptoms and shorten the clinical cure time, particularly for mild to moderate patients [35] [36] [37] . In view of the above postive clinical trials, the orally administered favipiravir has been authorized the emergency use for COVID-19 in India, Russia, Pakistan and other countries 38 . However, in December 2020, the Japanese government suspended the approval of favipiravir on the ground that it was difficult to judge its effectiveness. However, this did not negate its effectiveness, and Toyama Chemical Industry Co., Ltd. had decided to restart the clinical trial in Japan in May 2021, which will provide further evidence on its clinical efficacy and safety for the treatment of COVID-19.

Azvudine (4, FNC, Fig. 2 azide is the guarantee for azvudine to inhibit HIV and many other viruses [39] [40] .

However, the efficacy and safety in large sample-sized clinical trials still need to be further confirmed 41 .

β-D-N4-Hydroxycytidine (5, NHC, Fig. 2 ) is a N-hydrolyzed cytidine analog, which was initially applied to induce genetic mutation in bacteria 42 . Studies has proved its broad-spectrum activity towards a variety of RNA viruses, including HCoV-NL63 and SARS-CoV 43, 44 . Most importantly, NHC has been proved to effectively inhibit SARS-CoV-2 in cell culture and animal models, with an EC50 of 0.3 µmol/L in Vero E6 and 0.08 µM in Calu-3 45 . EIDD-2801 (6, Fig. 2 ) is NHC's esterified prodrug, endowed with better pharmacokinetic properties and almost equal activity (EC50 = 0.22 µmol/L) compared with NHC. When NHC molecules are integrated into the growing RNA chain, single mutations are formed and accumulated, leading to lethal mutagenesis in viral genome 46 . Moreover, NHC can effectively evade from proofreading mechanism and is hardly recognized or excised by ExoN. It has showed prominent activity against remdesivir-resistant SARS-CoV-2 strain 45 .

J o u r n a l P r e -p r o o f 

The conservation or similarity of the target in different viruses makes it a suitable option for repositioning of privileged structures. It means that the privileged structures proved to be effective on the target of a known virus, and these structures potentially be effective on a similar target of a novel virus.

Camostat (13, Fig. 5 ), targeting TMPRSS2 and related serine proteases, has been clinically used in the treatment of chronic pancreatitis. Shirato et al. 52 Recently, researchers at University of Chicago used the strategy of "drug repurposing" to seek anti-SARS-CoV-2 agents from 1900 approved drugs 56 . Masitinib, an oral tyrosine kinase inhibitor, was found to competitively inhibit the activity of the SARS-CoV-2 main protease, thereby inhibiting the replication of SARS-CoV-2 (18, Fig. 7 ). The antiviral activity of masitinib in transgenic mice model was evaluated, which showed that the treatment of masitinib reduced the titer of SARS-CoV-2 in lungs and nose to less than 1% only in 6 days. At the same time, the lung inflammation was also decreased. Furthermore, masatinib was also effective on various mutant strains of SARS-CoV-2 (alpha, beta and gamma).

The structure of masitinib and its position in the M pro (PDB code: 7JU7).

Virtual screening, as a complementay stragety to high-throughput screening 57 , has been a powerful approach in seeking effective anti-coronavirus drugs owing to the development of bioscience and computer-assisted drug design (CADD) 58,59 .

Dipyridamole ( Unlike traditional nucleoside RdRp inhibitors, Omipalisib has a novel scaffold and more interaction with nearby amnio acid residues, thus it is a valuable hit targeting RdRp for further optimization.

The structure of dipyridamole and omipalisib.

Zhai screened about 500 thousand bioactive molecules by docking method, and built a 

The structures of compounds 23 and 24.

The method of high throughput screening (HTS) in vitro can screen massive compounds and determine their biological activity in a short time. There are mainly two types of HTS: target-based HTS and fragment-based HTS and these two methods are often combined to discover new hit compounds.

Tripathi et al. 69 

The structures of nitazoxanide and PF-03882845.

High-resolution cocrystal structures confirmed the mechanism of action and illuminated the structural determinants involved in binding. In drug discovery, targetbased rational drug design is applied for the identification of potential drug candidates of therapeutic interest according to ligand-target interactions. Molecular docking provides a powerful tool to probe fundamental biological questions at atomistic level.

In the SARS-CoV-2 replication cycle, the major drug targets are M pro , PL pro , RdRp, Spike protein and ACE2. In 2020, Jin et al. 79 In addition, seeking non-covalent M pro inhibitors is also of great significance.

Perampanel (39, Fig. 16 ) was identified as a weak SARS-CoV-2 M pro inhibitor through kinetic assay 82 . According to Zhang's work 83 and occupied S1, S2 and S1′ pockets of the catalytic center. The initial modification of Perampanel produced compound 40, with IC50 value in single-digit micromolar level ( Fig. 16) . Subsequently, the researcher extended substituent groups of phenyl ring in S2 pocket to occupy S3 and S4 pocket, leading to the discovery of 41 with an enhanced activity (Fig. 16 ) 83 . Compound 42 (Fig. 16) was also synthesized in their following work, and showed favorable activity and solubility 84 .

Structures of perampanel and compounds 40-42.

PL pro , also known as nsp3, is responsible for three additional cuts in viral polyproteins.

Recent studies shed light on PL pro 's mechanism of suppressing immune response of host cell and facilitate coronavirus infection 85 , making it a valuable antiviral target.

Rut analyzed amnio acid sequence of PL pro cleavage site and used library-derived substrates to further study its substrate specificity 86 

The structure of compounds 45 and 46.

Viral RdRp is conserved in many virus families 88 . Hence, it is an idealistic target to develop inhibitors active against many different coronaviruses (Fig. 19A) .

Coronaviruses have large genomes and relatively lower mutation rates compared to other RNA viruses, mainly because the ExoN activity provides some proofreading capability that increases the fidelity of viral genome replication.

Remdesivir (Fig. 2) mechanism. remdesivir is first converted to its triphosphate metabolite (refered to as remdesivir triphosphate, RTP) form, which acts as a substrate of RdRp (Fig. 20) . Then remdesivir monophosphate (RMP) was incorporated into the growing RNA chain, with three more normal nucleotides followed. At this moment, C1ʹ-cyano group on the RMP ribose ring immediately clashes with Ser861 residue in nsp12 sidechain, thus halts nsp12's continuous moving on RNA template and limits the following process of RNA replication (Fig. 20) . Under such a state, the 3ʹ-nucleotide is still buried in active center and can escape exonuclease proofreading to some extent, but not completely 92 .

Proofreading activity towards RMP-incorporated RNA chain may account for remdesivir's inadequate clinical efficiency 93 

Nsp14 of SARS-CoV-2 is bifunctional enzyme, as mentioned in Section 2. to an aromatic moiety. Some of the designed compounds, including 50 (Fig. 22) , have reached nanomolar level activity, along with excellent selectivity of human-source RNMT (RNA guanine-7-methyltransferase).

Targeting ExoN, several existing drugs were identified as its inhibitors, but it is still far from specific drug design and application 96 . For SARS-CoV-2, ExoN deficiency mutant is unable to replicate, thus highlights importance of ExoN inhibitors applied in either monotherapy or combined with RdRp inhibitors 97 .

The structures of SAM, sinefugin, compounds 49 and 50.

The combination of S glycoprotein and ACE2 initiates the SARS-CoV-2 replication cycle 18 . Researchers have dipicted the structure of the SARS-CoV-2 trimeric spike protein through cryo-electron microscopy (Fig. 23A ) and reveal that it contains two subunits, S1 and S2, which facilitate receptor-binding and membrane fusion process, respectively (Fig. 23B) 98 . The RBD which can bind ACE2 exists in S1 subunit. The process that S protein binding to the ACE2 induces complicated conformational changes, mediating the S protein switching from a prefusion conformation to a postfusion conformation 99 . The S1 and S2 subunits in viral S are the key components for virus binding, fusion and entry 100 . RBD located at the middle region of S1 subunit, and S2 subunit includes a fusion peptide (FP) and two heptapeptide repeats (HR1 and HR2) which can fuse with the target cell membrane (Fig. 23C) 101 . Therefore, the entry or fusion process is of great importance for viral replication and blocking the binding In 2019, Xia et al. 102 found that the optimized form of polypeptide OC43-HR2P, the compound EK1 (Table 1) Furthermore, it has been proven that the affinity between ACE2 and SARS-CoV-2 S glycoprotein is higher than that of SARS-CoV spike glycoprotein 99 

The structure of ACE2-Ig.

Natural products and traditional Chinese medicine (TCM) constitute essential resources to develop new drugs. Therefore, it is worthy of exploring to find SARS-CoV-2 inhibitors from natural products and TCM.

Natural products have also provided rich resources for the development of novel antiviral agents [113] [114] [115] Recently, Su et al. 117 identified a flavonoid natural product, baicalein (53, Fig.   26 ), as a non-covalent small-molecule inhibitors of SARS-CoV-2 M pro confirmed the co-crystal structure of the M pro in complex with 53 (EC50 = 1.69 µmol/L in Vero E6 cells). Remarkably, the co-crystal structure showed that baicalein can be perfectly fixed in the core of the substrate-binding pocket by interacting with several residues of M pro (L141−S144), and acting as a "shield" to protect the active site from any substrate approaching (Fig. 26 ). This unique binding mode, combined with its high 

The structure of myricetin and the X-ray costructure of myricetin in SARS-CoV-2 M pro (PDB code: 7DPP).

The current COVID-19 pandemic have brought major challenge to public health.

Since then, significant efforts have been made by scientists around the world and impressive progress has been gained in the research of structural biology, epidemiology and antiviral interventions of the SARS-CoV-2. Unfortunately, there are no effective drugs to combat SARS-CoV-2 until now. It is an enormous challenge for the development of effective drugs, especially for halting the suddenly outbroken SARS-CoV-2.

In face of this urgent situation, some strategies could facilitate the development of effective SARS-CoV-2 inhibitors. Firstly, drug repurposing involves the reuse of existing drugs for a new applications. The advantage of drug repurposing is that the drug security has been tested, so this method can bypass the pharmacokinetic, pharmacodynamic and toxic studies, resulting in entering phase Ⅱ or Ⅲ clinical trials directly, which will significantly promote the drug development process. The FDAapproved drug library, clinical and preclinical drug library and broad-spectrum antivirals library are the common libraries used for drug repurposing. Secondly, largescale screening in silico and in vitro can evaluate tens of millions of compounds efficiently, which will increase the amount and quality of novel inhibitors. To be noted, large-scale screening can facilitate new drug development only with the exception of false-positive results, along with further evaluation of antiviral activity 127 . Thirdly, de novo drug design based on the target is a rational process to design a new structure on a molecular level. This is a time-consuming process, but it is necessary to expand our drug reservoir to deal with the potential outbreak of potential coronavirus variants.

It's worth noting that SARS-CoV-2 has a highly mutative genetic sequence, In summary, the development of novel and effective SARS-CoV-2 inhibitors is urgently-needed to respond to the situation what we are facing now. Novel compounds are expected take a significant part in the combation against circulating and emerging coronavirus epidemic. We need to increase the investment in the basic research of antiviral drugs, to build the systematic platform for de novo drug design, lead compound discovery and optimization, drug-likeness evaluation and PK/PD study. In this way, enough drug reservoir could be developed to respond any possible coronavirus out break in the current crisis and future.

A new coronavirus associated with human respiratory disease in China

SARS-CoV-2 is an appropriate name for the new coronavirus

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

World Health Organization. Coronavirus disease 2019 (COVID-19) situation report-51

Coronavirus diversity, phylogeny and interspecies jumping

Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus

Acute life threatening event (ALTE) in an infant with human coronavirus HCoV-229E infection

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

World Health Organization. WHO recommends against the use of remdesivir in COVID-19 patients

A Trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19

A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

SARS-CoV-2 cell entry and targeted antiviral development

Characterization of the budding compartment of mouse hepatitis virus: evidence that transport from the RER to the Golgi complex requires only one vesicular transport step

Origin and evolution of pathogenic coronaviruses

Drug repositioning: identifying and developing new uses J o u r n a l P r e -p r o o f for existing drugs

Repurposing host-based therapeutics to control coronavirus and influenza virus

Structure-function relationships among RNAdependent RNA polymerases

Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNApolymerase

Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease

remdesivir for the treatment of COVID-19-final report

outcomes in hospitalized patients with COVID-19

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Experimental treatment with favipiravir for COVID-19: an open-label control study

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial

AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial

Role of favipiravir in the treatment of COVID-19

The pyrimidine analog FNC potently inhibits the replication of multiple enteroviruses

Mechanistic insight into antiretroviral potency of 2ʹ-eeoxy-2ʹ-β-fluoro-4ʹ-azidocytidine (FNC) with a longlasting effect on HIV-1 prevention

A randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study

Mutagenic action of N4-hydroxycytidine on Escherichia coli B cyt

Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine

Inhibition of human coronavirus NL63 infection at early stages of the replication J o u r n a l P r e -p r o o f cycle

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Nucleoside analogues for the treatment of coronavirus infections

Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway

Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis

Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters

Protease inhibitors targeting coronavirus and filovirus entry

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2

Integration of virtual and high-throughput screening

Docking and scoring in virtual screening for drug discovery: methods and applications

Improving small molecule virtual screening strategies for the next generation of therapeutics

Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation

Anti-platelet therapy: phosphodiesterase inhibitors

Mechanism of action of dipyridamole

Inhibition of herpes simplex virus reactivation by dipyridamole

Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction

Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant

Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay

Structure-based discovery of novel nonpeptide inhibitors targeting SARS-CoV-2 Mpro

Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2

Biochemical screening for SARS-CoV-2 main protease inhibitors

Structural basis of mismatch recognition by a SARS-CoV-2 proofreading enzyme

Coupling of N7-methyltransferase and 3'−5' exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading

Development of a high-throughput screening assay to identify inhibitors of the SARS-CoV-2 guanine-N7-methyltransferase using RapidFire mass spectrometry

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase

Coronaviruses-drug discovery and therapeutic options

Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases

National Health Commission of China

HIV-1 protease inhibitors: effects on HIV-2 replication and resistance

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model

Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2

Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations

Optimization of triarylpyridinone inhibitors of the main protease of SARS-CoV-2 to low-nanomolar antiviral potency

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design

X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases

Structure-function relationships among RNAdependent RNA polymerases, RNA interference

First case of 2019 novel coronavirus in the United States

Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

RNA 3ʹ-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex

Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease

Potent SARS-CoV-2 mRNA cap methyltransferase inhibitors by bioisosteric replacement of methionine in SAM cosubstrate

The structurebased design of SARS-CoV-2 nsp14 methyltransferase ligands yields nanomolar inhibitors

Combination of antiviral drugs to inhibit SARS-CoV-2 polymerase and exonuclease as potential COVID-19 therapeutics. bioRxiv 2021

The enzymatic activity of the nsp14 exoribonuclease is critical for replication of MERS-CoV and SARS-CoV-2

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor

De Novo design of αhelical lipopeptides targeting viral fusion proteins: a promising strategy for relatively broad-spectrum antiviral drug discovery

Targeting the entry step of SARS-CoV-2: a promising therapeutic approach

Inhibitors of SARS-CoV-2 entry: current and future opportunities

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

De novo design of picomolar SARS-CoV-2 miniprotein inhibitors

Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2

Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator

Structural basis for the recognition J o u r n a l P r e -p r o o f of SARS-CoV-2 by full-length human ACE2

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

Drug discovery from natural products

The re-emergence of natural products for drug discovery in the genomics era

The evolving role of natural products in drug discovery

Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019

Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients

Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro

Tubulin bound to colchicine forms polymers different from microtubules

The use of colchicine in respiratory diseases or current respiratory medicine

Colchicine and SARS-CoV-2: management of the hyperinflammatory state

Sequential doxycycline and colchicine combination therapy in COVID-19: the salutary effects

Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition

Glycyrrhizin effectively inhibits SARS-CoV-2 replication by inhibiting the viral main protease

Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease

Recent advances in developing small-molecule inhibitors against SARS-CoV-2

Discovery of SK-575 as a highly potent and efficacious proteolysis-targeting chimera degrader of PARP1 for treating cancers

Targeting the SARS-CoV-2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders

We gratefully acknowledge financial support from the Shandong Provincial Key